Maybe - Chimeric does have a much lower valuation despite having multiple assets and multiple ongoing clinical trials - definitely the more asymmetric bet.
I think Arovella may have been accumulated by investors speculating a buyout/licensing from Imugene. Which of course is quite possible.
Breakout Looming?, page-338
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $200.3M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 18.0¢ | $196.7K | 1.060M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 781535 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 675597 | 4 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |